The mission of Cure JM is to find better treatments and a cure for juvenile myositis and improve the lives of families affected by JM, including juvenile dermatomyositis (JDM) and juvenile polymyositis (JPM), a group of rare and life-threatening autoimmune diseases in which the body’s immune system attacks its own cells and tissues.
To advance this mission, Cure JM welcomes Letters of Intent for its research grants program. Through the program, grants will be awarded in support of innovative approaches in the treatment of juvenile myositis. A list of research priorities includes analyses of samples and/or data available from innovative treatment clinical studies; collaboration with pharma companies or other research organizations aimed at developing new therapies that may have utility in the treatment of juvenile myositis; clinical protocols for repurposed drugs for the treatment of juvenile myositis; and investigations of in vitro or in vivo models of juvenile myositis with the objective of development of new therapies.
In 2021, Cure JM has committed to fund new research grants of up to $75,000 per year for up to two years, with preference given to individuals who have at least 25 percent protected research time from their institution.
To be eligible, applicants must hold a PhD or MD degree or equivalent and work in an accredited medical school, university, hospital, or research institute that agrees to supply the clinical and/or laboratory facilities. The foundation strongly encourages collaborations from two or more institutions that bring together a spectrum of expertise.
Letters of Intent are due May 14. Upon review, selected applicants will be invited to submit a full application by June 15, 2021.
See the Cure JM website for complete program guidelines and application instructions.